Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia

Abstract

Objectives: To investigate the efficacy of tadalafil for patients with benign prostatic hyperplasia and especially with chronic prostatitis/chronic pelvic pain syndrome.Methods: Tadalafil 5 mg was given each morning for 12 weeks to patients diagnosed as having either moderate or severe lower urinary tract symptoms. Voiding symptoms were compared between patients with a high (>4; high group) and low (<4; low group) pain subscore of the National Institutes of Health Chronic Prostatitis Symptom Index before and after tadalafil administration. Correlation between changes in the Chronic Prostatitis Symptom Index and the International Prostate Symptom Score during treatment was also investigated.Results: At the pretreatment baseline, the pain subscore of the Chronic Prostatitis Symptom Index was high (>4) in 24 of 74 (32.4%) patients. The International Prostate Symptom Score in the group with high pain subscore was significantly higher than that in the group with low pain subscore. As an indicator of the efficacy of tadalafil, the International Prostate Symptom Score and National Institutes of Health Chronic Prostatitis Symptom Index total score and pain subscore were significantly improved.The change in the Chronic Prostatitis Symptom Index total score correlated positively with the change in the International Prostate Symptom Score. The decrease in the 4 International Prostate Symptom Score was significantly greater in the group with high versus low pain subscore. Conclusion:Tadalafil was sufficiently effective in the treatment of patients with benign prostatic hyperplasia and severe chronic prostatitis/chronic pelvic pain syndrome.

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

“…Although several PDE5Is (sildenafil, tadalafil, and vardenafil) have been reported to exert efficacy on LUTS-BPH patients, only tadalafil has been approved by the FDA to treat patients with BPH (Hiramatsu et al, 2020). PDE5Is were initially developed to treat ED.…”

History of Prostatitis Is an Independent Risk Factor for Erectile Dysfunction: A Cross-Sectional Study

“…The coexistence of these conditions is interesting in that evidence suggests a link between prostatitis and ED though the reason is unclear. One study had shown that tadalafil, a classic drug for ED, is also effective for treating prostatitis [ 10 ]. In recent years, lots of articles have revealed that a high prevalence of ED ranges from 15.0% to 40.5% among patients with CP/CPPS in China; it is not enough to explain the relationship based on the current research data [ 11 , 12 ].…”

Nonablative transurethral Erbium:YAG laser treatment for chronic prostatitis/chronic pelvic pain syndrome: A prospective comparative study

“…The IPSS scores were very significantly decreased after both treatments and the results have persisted up to the 12‐month follow‐up. Hiramatsu et al 31 have recently found that tadalafil administration led to a larger decrease of IPSS scores in patients with benign prostatic hyperplasia that also had more severe pain scores, compared to those that did not experience high levels of pain. That is consistent with our results, as all of the patients in our study had high pain scores and have shown very pronounced IPSS improvement after both treatments (Figure 2).…”

“…Urinary symptoms were evaluated using different outcome measures: Objectively, by measuring the maximum urethral flow value (Q-max) using uroflowmetry; and subjectively, using the International Prostate Symptom Score (IPSS) questionnaire, which consists of seven questions concerning urinary symptoms and one question concerning quality of life. 15 The IPSS total score range is from 0 to 35, from asymptomatic (score 0), mildly symptomatic (1-7), moderately symptomatic (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) to severely symptomatic (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35).…”